Literature DB >> 33689775

Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).

Yihe Yan1, Leting Zheng2, Qiang Du3, Hamza Yazdani3, Kun Dong3, Yarong Guo3, David A Geller4.   

Abstract

Interferon regulatory factor 1 (IRF-1) is a tumor suppressor gene in cancer biology with anti-proliferative and pro-apoptotic effect on cancer cells, however mechanisms of IRF-1 regulating tumor microenvironment (TME) in hepatocellular carcinoma (HCC) remain only partially characterized. Here, we investigated that IRF-1 regulates C-X-C motif chemokine 10 (CXCL10) and chemokine receptor 3 (CXCR3) to activate anti-tumor immunity in HCC. We found that IRF-1 mRNA expression was positively correlated with CXCL10 and CXCR3 through qRT-PCR assay in HCC tumors and in analysis of the TCGA database. IRF-1 response elements were identified in the CXCL10 promoter region, and ChIP-qPCR confirmed IRF-1 binding to promote CXCL10 transcription. IRF-2 is a competitive antagonist for IRF-1 mediated transcriptional effects, and overexpression of IRF-2 decreased basal and IFN-γ induced CXCL10 expression. Although IRF-1 upregulated CXCR3 expression in HCC cells, it inhibited proliferation and exerted pro-apoptotic effects, which overcome proliferation partly mediated by activating the CXCL10/CXCR3 autocrine axis. In vitro and in vivo studies showed that IRF-1 increased CD8+ T cells, NK and NKT cells migration, and activated IFN-γ secretion in NK and NKT cells to induce tumor apoptosis through the CXCL10/CXCR3 paracrine axis. Conversely, this effect was markedly abrogated in HCC tumor bearing mice deficient in CXCR3. Therefore, the IRF-1/CXCL10/CXCR3 axis contributes to the anti-tumor microenvironment in HCC.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemokine; Chemokine receptor; Hepatocellular carcinoma; IRF-1; Tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33689775      PMCID: PMC8009854          DOI: 10.1016/j.canlet.2021.03.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  50 in total

1.  Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response.

Authors:  Jianbing Huang; Jiagen Li; Yuan Li; Zhiliang Lu; Yun Che; Shuangshuang Mao; Yuanyuan Lei; Ruochuan Zang; Sufei Zheng; Chengming Liu; Xinfeng Wang; Ning Li; Nan Sun; Jie He
Journal:  Cancer Lett       Date:  2019-06-05       Impact factor: 8.679

2.  CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.

Authors:  Erik Wennerberg; Veronika Kremer; Richard Childs; Andreas Lundqvist
Journal:  Cancer Immunol Immunother       Date:  2014-10-26       Impact factor: 6.968

3.  Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1).

Authors:  Peiyuan Li; Qiang Du; Zongxian Cao; Zhong Guo; John Evankovich; Wei Yan; Ying Chang; Lifang Shao; Donna Beer Stolz; Allan Tsung; David A Geller
Journal:  Cancer Lett       Date:  2011-10-01       Impact factor: 8.679

4.  Nitric oxide production upregulates Wnt/β-catenin signaling by inhibiting Dickkopf-1.

Authors:  Qiang Du; Xinglu Zhang; Quan Liu; Xianghong Zhang; Christian E Bartels; David A Geller
Journal:  Cancer Res       Date:  2013-09-05       Impact factor: 12.701

5.  IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production.

Authors:  Shinichiro Yokota; Osamu Yoshida; Lei Dou; Anthony V Spadaro; Kumiko Isse; Mark A Ross; Donna B Stolz; Shoko Kimura; Qiang Du; Anthony J Demetris; Angus W Thomson; David A Geller
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

Review 6.  Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.

Authors:  Amy L Shergold; Rhona Millar; Robert J B Nibbs
Journal:  Pharmacol Res       Date:  2019-05-04       Impact factor: 7.658

7.  p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha.

Authors:  S Majumder; L Z Zhou; P Chaturvedi; G Babcock; S Aras; R M Ransohoff
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

Review 8.  Tumor Immunology and Tumor Evolution: Intertwined Histories.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Immunity       Date:  2020-01-14       Impact factor: 31.745

9.  IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.

Authors:  Lulu Shao; Weizhou Hou; Nicole E Scharping; Frank P Vendetti; Rashmi Srivastava; Chandra Nath Roy; Ashley V Menk; Yiyang Wang; Joe-Marc Chauvin; Pooja Karukonda; Stephen H Thorne; Veit Hornung; Hassane M Zarour; Christopher J Bakkenist; Greg M Delgoffe; Saumendra N Sarkar
Journal:  Cancer Immunol Res       Date:  2019-06-25       Impact factor: 12.020

10.  Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.

Authors:  B Cambien; B F Karimdjee; P Richard-Fiardo; H Bziouech; R Barthel; M A Millet; V Martini; D Birnbaum; J Y Scoazec; J Abello; T Al Saati; M G Johnson; T J Sullivan; J C Medina; T L Collins; A Schmid-Alliana; H Schmid-Antomarchi
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more
  2 in total

1.  Functionally Antagonistic Transcription Factors IRF1 and IRF2 Regulate the Transcription of the Dopamine Receptor D2 Gene Associated with Aggressive Behavior of Weaned Pigs.

Authors:  Jing Zhao; Siyuan Gao; Yanli Guo; Qinglei Xu; Mingzheng Liu; Chunlei Zhang; Meng Cheng; Xianle Zhao; Allan P Schinckel; Bo Zhou
Journal:  Biology (Basel)       Date:  2022-01-14

2.  A miR-212-3p/SLC6A1 Regulatory Sub-Network for the Prognosis of Hepatocellular Carcinoma.

Authors:  Dan-Dan Zhang; Wen-Er Wang; Yu-Shui Ma; Yi Shi; Jie Yin; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Da Fu; Wen-Jie Zhang
Journal:  Cancer Manag Res       Date:  2021-06-28       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.